Status:
COMPLETED
DreaMS - Digital Biomarkers for Multiple Sclerosis
Lead Sponsor:
Research Center for Clinical Neuroimmunology and Neuroscience Basel
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The Investigators have developed the dreaMS App, a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). Through the use of app-based tests, surveys...
Detailed Description
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) causing focal lesions of demyelination and diffuse neurodegeneration in the grey and white matter of the b...
Eligibility Criteria
Inclusion
- Patients with MS
- Age 18-70
- Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (CIS, RRMS, SPMS, PPMS)
- EDSS ≤ 6.5
- In possession of a smart phone
Exclusion
- Age \<18 and \> 70
- EDSS \> 6.5
- Other clinically significant concomitant disease states (e.g., renal failure, severe hepatic dysfunction, severe/unstable cardiovascular disease, progressive cancer, etc.)
- Known or suspected non-compliance, drug or alcohol abuse
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
- Women who are pregnant or breast feeding
- Not in possession of a smart phone
- Healthy Volunteers
- Inclusion Criteria:
- Age 18-70
- In possession of a smart phone
Key Trial Info
Start Date :
October 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 26 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04413032
Start Date
October 5 2020
End Date
February 26 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RC2NB
Basel, Switzerland, 4031